Goldman Sachs says the range of possible outcomes on the variant is ‘unusually wide’.
It could have sizeable growth impacts but the range of possibilities, including a false alarm, means they are not presently making any changes to their forecasts:
- until the likelihood of these scenarios has become somewhat clearer
Meanwhile, Credit Suisse analysts say that the anti-viral pills will remain effective
- as they are not designed to target spike proteins
(where mutations occur) in the way vaccines are
- at worse this
postpones, not cancels, an economic recovery